Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Fosbretabulin - Oncotelic Therapeutics

Drug Profile

Fosbretabulin - Oncotelic Therapeutics

Alternative Names: CA4DP; CA4P; Combretastatin A-4 phosphate - Oncotelic Therapeutics; Combretastatin A4 prodrug; Combretastatin-A4; Combretastatin-A4 phosphate; CRC 87-09; CRC-98-09; CS-A4; Fosbretabulin disodium; Fosbretabulin tromethamine; NSC-613729; Zybrestat®

Latest Information Update: 28 Jun 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Arizona State University
  • Developer Mateon Therapeutics; National Cancer Institute (USA); Oncotelic Therapeutics; OXiGENE; University of Aarhus; University of Florida; University of Kentucky
  • Class Antineoplastics; Antipsoriatics; Antirheumatics; Combretastatins; Eye disorder therapies; Small molecules; Stilbenes
  • Mechanism of Action Cadherin 5 inhibitors; Tubulin polymerisation inhibitors; Vascular disrupting agents
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Glioma; Neuroendocrine tumours; Thyroid cancer; Ovarian cancer
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Cancer; Malignant melanoma
  • Discontinued Age-related macular degeneration; Colorectal cancer; Diabetic retinopathy; Fallopian tube cancer; Gastrointestinal cancer; Head and neck cancer; Leukaemia; Malignant carcinoid syndrome; Neuroendocrine tumours; Non-small cell lung cancer; Ovarian cancer; Pancreatic cancer; Peritoneal cancer; Polypoidal choroidal vasculopathy; Psoriasis; Rheumatoid arthritis; Thyroid cancer

Most Recent Events

  • 28 Jun 2023 No recent reports of development identified for clinical-Phase-Unknown development in Malignant-melanoma(Combination therapy, Second-line therapy or greater) in Unknown (IV)
  • 28 Jun 2023 No recent reports of development identified for clinical-Phase-Unknown development in Malignant-melanoma(Monotherapy, Second-line therapy or greater) in Unknown (IV)
  • 11 May 2022 Oncotelic Therapeutics has patent protection for CA4P in USA
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top